High Chromosome Number in Blood Cancer Cells Predicts Poor Response to Treatment
Author Information
Author(s): Moy Christopher, Oleykowski Catherine A, Plant Ramona, Greshock Joel, Jing Junping, Bachman Kurtis, Hardwicke Mary Ann, Wooster Richard, Degenhardt Yan
Primary Institution: GlaxoSmithKline Oncology Research
Hypothesis
Does a high chromosome number in hematological cancer cell lines predict resistance to the Aurora B and C inhibitor GSK1070916?
Conclusion
High chromosome number is associated with resistance to the inhibition of Aurora B and C, suggesting it could serve as a negative predictive marker for GSK1070916.
Supporting Evidence
- 20 out of 59 cell lines were sensitive to GSK1070916, while 39 were resistant.
- High chromosome number was more prevalent in resistant cell lines.
- Polyploid subpopulations were associated with greater resistance.
- NOTCH1 mutation status was linked to high chromosome number in T-ALL cell lines.
Takeaway
If blood cancer cells have a lot of chromosomes, they might not respond well to a certain treatment. This could help doctors know which patients might not benefit from the drug.
Methodology
The study used 59 hematological cancer cell lines to assess their sensitivity to GSK1070916 based on cell death and analyzed karyotype, transcriptomics, and mutation profiles.
Potential Biases
Potential bias due to the exclusion of discordant cell lines and reliance on established cell lines.
Limitations
The study did not perform re-authentication of cell lines and excluded some subclones from analysis.
Participant Demographics
The study focused on hematological cancer-derived cell lines without specific demographic details.
Statistical Information
P-Value
0.0098
Confidence Interval
95% CI 0.0284-0.1044
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website